Evidence map›Paper›PMID 41189975›Full record

ArticleFrontiers in public health2025

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria.

Michaela Höck, Wegene Borena, Jürgen Brunner, Karina Wechselberger, Johanna Scheiring, Elisabeth Ralser, Ulrike Pupp Peglow, Peter Wöckinger, Elisabeth D'Costa, Verena Kaiser and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michaela Höck *Department of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria.
Wegene Borena *Department of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Jürgen BrunnerDepartment of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
Karina WechselbergerDepartment of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria.
Johanna ScheiringDepartment of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria.
Elisabeth RalserDepartment of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria.
Ulrike Pupp PeglowDepartment of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria.
Peter WöckingerDepartment of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria.
Elisabeth D'CostaDepartment of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria.
Verena KaiserDepartment of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
Klaus KapelariDepartment of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
Gisa GeroldDepartment of Hygiene, Microbiology and Virology, Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
Thomas MüllerDepartment of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.
Ursula Kiechl-KohlendorferDepartment of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria.
Elke GriesmaierDepartment of Pediatrics II, Medical University of Innsbruck, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Since summer 2024, passive immunization with nirsevimab (Beyfortus Objective: This study aimed to assess the acceptance and impact of RSV immunization strategies during the 2024/2025 season in Tyrol, Austria. Methods: A retrospective study was conducted analyzing all live births at three Tyrolean maternity wards (Innsbruck, Hall, and Schwaz) from 5 December 2024 to 15 April 2025. Immunization rates were analyzed, and RSV-related hospitalization frequency and duration were compared to pre-pandemic seasons. Results: Of 1,156 newborns, 57% received nirsevimab and 12% were protected by maternal RSVpreF protection, resulting in an overall coverage of almost 70%. RSV-related hospitalizations for infants under 1 year of age significantly decreased from 151 in pre-pandemic seasons to 47 in the post-nirsevimab season ( Conclusion: Our findings highlight the positive impact of both RSV immunization strategies-nirsevimab and RSVpreF vaccine-while underscoring the need to enhance public awareness and education to improve immunization rates. Future immunization programs must be strengthened to provide better protection for the pediatric population and reduce RSV-associated morbidity in early life.

Indexed as

Antibodies, Monoclonal, HumanizedPatient Acceptance of Health CareRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAdultAustriaFemaleHospitalizationHumansInfantInfant, NewbornMalePregnancyRetrospective StudiesAntibodies, Monoclonal, HumanizedRespiratory Syncytial Virus VaccinesacceptancenewbornnirsevimabRSVRSVpreF vaccine

Identifiers

PMID41189975
PMCPMC12580268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.